๐ A major market shock is expected on Monday due to the buyback blackout period beginning, which historically leads to a decline in stock prices.
๐ฒ Corporate stock buybacks have been the major driver of equity purchases, with authorization reaching 789 billion dollars year to date.
๐ Goldman predicts a 30 to 50 percent decline in trading volume during the blackout period, signaling a significant impact on the market.
๐ก Negative sentiment and positioning indicate a major market shock is expected.
โ ๏ธ Machines' positioning in US and global equities suggest a downward trend.
๐ Technical signals show a potential decrease in momentum.
๐ The S&P is showing signs of a lower high, indicating a potential downside move.
๐ป Momentum in the tech sector is slowing down and rolling over, with concerns about tech companies buying back stocks.
๐ The QQQ is also showing signs of a lower high, suggesting a possible market decline.
๐ผ TLT momentum is negative, with a consecutive daily sell signal, suggesting a downward trend.
๐ On the upside, adding another position on TLT when it moves off the Max short is recommended with a target of 97.25.
๐ Gold is forming a massive topping pattern, indicating it's more likely to be sold than bought.
๐ The 100-day moving average indicates a topping pattern, suggesting people are selling.
๐ GDX shows signs of a topping pattern, with sellers waiting for buyers to come in.
โ ๏ธ There is a potential major buying opportunity if GDX drops to around 18.
๐ Silver is likely to break down, with negative momentum and consecutive sell signals.
๐ SLV has a topping pattern, with sellers above and a potential target of 18.
๐ Momentum is positive for King Joller, suggesting it is overbought.
๐ The Invesco dollar bearish fund (UDN) shows potential for a reversal in the dollar's downward trend.
๐ฐ The Platinum trade demonstrates multiple buying opportunities and the potential for a positive return.
๐ Mira Pharmaceuticals (MIRA) is a promising stock with the potential for a significant upside movement.
๐ The stock of Mira 1A has experienced a massive wave of selling and is now considered massively oversold.
๐ Mira 1A is a prescription medication being developed with a better side effect profile and is focused on three therapeutic areas: neuropathic pain, anxiety, and cognitive decline.
๐ฌ Mira 1A has demonstrated its ability to enhance memory, improve cognitive performance, reduce pain, and relieve anxiety in pre-clinical research.